Biophytis Unveils Its Outlook Strategies for 2025
Biophytis SA (FP: ALBPS), a clinical-stage biotech company, has announced its strategic outlook for 2025, highlighting recent achievements and future plans. The company has strengthened its position through several key initiatives, including: launching the OBA clinical development program for obesity treatment, signing a strategic licensing agreement with Blanver, entering exclusive negotiations with a major Chinese pharmaceutical company, and establishing a co-development agreement with AskHelpU in ALS.
The company plans to accelerate the clinical development and commercialization of BIO101 (20-Hydroxyecdysone). Key initiatives include initiating Phase 2 OBA study for obesity treatment in collaboration with Blanver, targeting the obesity market projected to reach $100 billion by 2030. Additionally, Biophytis plans to launch Phase 3 of its SARA clinical program for sarcopenia, addressing a market of approximately 30 million patients in China with growing prevalence in Europe and the United States.
Biophytis SA (FP: ALBPS), una società biotech in fase clinica, ha annunciato la sua prospettiva strategica per il 2025, evidenziando i risultati recenti e i piani futuri. L'azienda ha rafforzato la sua posizione attraverso diverse iniziative chiave, tra cui: il lancio del programma di sviluppo clinico OBA per il trattamento dell'obesità, la firma di un accordo di licenza strategica con Blanver, l'avvio di negoziazioni esclusive con un'importante azienda farmaceutica cinese e la creazione di un accordo di co-sviluppo con AskHelpU in ALS.
La società prevede di accelerare lo sviluppo clinico e la commercializzazione di BIO101 (20-idrossiecdisone). Le iniziative chiave comprendono l'avvio dello studio OBA di Fase 2 per il trattamento dell'obesità in collaborazione con Blanver, mirando a un mercato dell'obesità che si prevede raggiunga i 100 miliardi di dollari entro il 2030. Inoltre, Biophytis prevede di lanciare la Fase 3 del suo programma clinico SARA per la sarcopenia, affrontando un mercato di circa 30 milioni di pazienti in Cina con una crescente prevalenza in Europa e Stati Uniti.
Biophytis SA (FP: ALBPS), una empresa biotecnológica en fase clínica, ha anunciado su perspectiva estratégica para 2025, destacando los logros recientes y los planes futuros. La compañía ha fortalecido su posición a través de varias iniciativas clave, que incluyen: el lanzamiento del programa de desarrollo clínico OBA para el tratamiento de la obesidad, la firma de un acuerdo de licencia estratégica con Blanver, la entrada en negociaciones exclusivas con una importante empresa farmacéutica china y el establecimiento de un acuerdo de co-desarrollo con AskHelpU en ALS.
La empresa planea acelerar el desarrollo clínico y la comercialización de BIO101 (20-Hidroxiecdisona). Las iniciativas clave incluyen iniciar el estudio OBA de Fase 2 para el tratamiento de la obesidad en colaboración con Blanver, apuntando al mercado de la obesidad que se prevé alcance los 100 mil millones de dólares para 2030. Además, Biophytis planea lanzar la Fase 3 de su programa clínico SARA para la sarcopenia, abarcando un mercado de aproximadamente 30 millones de pacientes en China con una creciente prevalencia en Europa y Estados Unidos.
Biophytis SA (FP: ALBPS), 임상 단계 바이오텍 기업이 2025년 전략적 전망을 발표하였으며, 최근 성과와 미래 계획을 강조하였습니다. 이 회사는 비만 치료를 위한 OBA 임상 개발 프로그램 출시, Blanver와의 전략적 라이선스 계약 체결, 주요 중국 제약 회사와의 독점 협상 진입, ALS에 대한 AskHelpU와의 공동 개발 계약 체결 등 여러 주요 이니셔티브를 통해 입지를 강화하였습니다.
회사는 BIO101 (20-하이드록시엑디손)의 임상 개발 및 상용화를 가속화할 계획입니다. 주요 이니셔티브에는 Blanver와의 협력을 통해 비만 치료를 위한 OBA 2상 연구 시작이 포함되어 있으며, 2030년까지 1,000억 달러에 달할 것으로 예상되는 비만 시장을 목표로 하고 있습니다. 또한 Biophytis는 근감소증을 위한 SARA 임상 프로그램의 3단계를 출시할 계획이며, 이는 유럽과 미국에서 증가하는 유병률을 갖춘 중국의 약 3천만 환자를 대상으로 합니다.
Biophytis SA (FP: ALBPS), une entreprise biopharmaceutique en phase clinique, a annoncé ses perspectives stratégiques pour 2025, mettant en avant ses réalisations récentes et ses projets futurs. L'entreprise a renforcé sa position grâce à plusieurs initiatives clés, notamment : le lancement du programme de développement clinique OBA pour le traitement de l'obésité, la signature d'un accord de licence stratégique avec Blanver, l'entrée en négociations exclusives avec une grande entreprise pharmaceutique chinoise et l'établissement d'un accord de co-développement avec AskHelpU en ALS.
L'entreprise prévoit d'accélérer le développement clinique et la commercialisation de BIO101 (20-Hydroxyecdysone). Les initiatives clés comprennent le démarrage de l'étude OBA de Phase 2 pour le traitement de l'obésité en collaboration avec Blanver, visant un marché de l'obésité qui devrait atteindre 100 milliards de dollars d'ici 2030. De plus, Biophytis prévoit de lancer la Phase 3 de son programme clinique SARA pour la sarcopénie, s'attaquant à un marché d'environ 30 millions de patients en Chine avec une prévalence croissante en Europe et aux États-Unis.
Biophytis SA (FP: ALBPS), ein biotechnologisches Unternehmen in der klinischen Phase, hat seinen strategischen Ausblick für 2025 angekündigt und dabei kürzliche Erfolge sowie zukünftige Pläne hervorgehoben. Das Unternehmen hat seine Position durch mehrere wichtige Initiativen gestärkt, einschließlich: dem Start des OBA-Programms zur klinischen Entwicklung zur Behandlung von Fettleibigkeit, dem Abschluss eines strategischen Lizenzvertrags mit Blanver, dem Eintreten in exklusive Verhandlungen mit einem großen chinesischen Pharmaunternehmen und dem Abschluss eines Kooperationsentwicklungsvertrags mit AskHelpU in Bezug auf ALS.
Das Unternehmen plant, die klinische Entwicklung und Vermarktung von BIO101 (20-Hydroxyecdysone) zu beschleunigen. Zu den wichtigsten Initiativen gehört der Beginn der Phase-2-Studie OBA zur Behandlung von Fettleibigkeit in Zusammenarbeit mit Blanver, die auf den Fettleibigkeitsmarkt abzielt, der bis 2030 voraussichtlich 100 Milliarden Dollar erreichen wird. Darüber hinaus plant Biophytis, die Phase 3 seines klinischen SARA-Programms zur Sarkopenie einzuführen, das sich auf einen Markt von etwa 30 Millionen Patienten in China konzentriert, mit zunehmender Prävalenz in Europa und den Vereinigten Staaten.
- Strategic expansion through multiple partnerships (Blanver, Chinese pharma company, AskHelpU)
- Targeting obesity market projected to reach $100 billion by 2030
- Addressing sarcopenia market with 30 million potential patients in China alone
- Advanced pipeline with upcoming Phase 2 and Phase 3 trials
- None.
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 11, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today unveils its strategic outlook for the year 2025.
Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap:
- Launch of the OBA clinical development program for the treatment of obesity,
- Strategic licensing agreement signed with Blanver,
- Entry into exclusive negotiations with a major Chinese pharmaceutical company,
- Conclusion of a co-development agreement with AskHelpU in ALS,
- Strengthening its financial structure.
2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 (20-Hydroxyecdysone) and its commercialization. In line with Biophytis' business model and partnership strategy, the company will actively pursue agreements and collaborations in the Americas, Europe and Asia, in order to expand its presence in key indications, notably obesity and sarcopenia.
Biophytis will also initiate the Phase 2 OBA study for BIO101 (20-Hydroxyecdysone) in obesity, in collaboration with Blanver and other potential partners. This study will evaluate the efficacy of BIO101 (20-Hydroxyecdysone) in obese patients treated with GLP-1 RAs and following a hypocaloric diet. With a rapidly expanding obesity market estimated to reach
Finally, Biophytis plans to launch phase 3 of its SARA clinical program in the coming months, aimed at confirming the efficacy of BIO101 (20-Hydroxyecdysone) in sarcopenia. This indication represents a major unresolved public health issue, with a rapidly expanding market representing some 30 million patients in China and a growing prevalence in Europe and the United States.
Stanislas Veillet, CEO of Biophytis, commented: "Following major clinical advances and the conclusion of key strategic partnerships, we are continuing to execute our roadmap, confirming our commitment to addressing crucial public health issues, particularly in obesity and sarcopenia. Our mission is to bring therapeutic solutions to the patients who need them most, while consolidating our growth and impact across all key geographies."
Biophytis has published a letter to shareholders, available on the company's website (www.biophytis.com), to share its progress to 2024 and its strategic outlook for 2025.
* * * *
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready tò start, and Duchenne muscular dystrophy, phase 1-2 to start), respiratory (Covid-19, phase 2-3 complete) and metabolic (obesitý, phase 2 to start) diseases. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADSs (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For further information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook", "believes", "expects", "potential", "continues", "may", "will", "should", "could", "seeks", "predicts", "intends", "trends", "plans", "estimates", "anticipates" or the negative version of these words or other comparable words. These forward-looking statements are based on assumptions that Biophytis considers reasonable. However, there can be no assurance that the statements contained in these forward-looking statements will prove to be correct, as they are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not presently known to Biophytis or that Biophytis currently deems immaterial. Consequently, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements. Please also refer to the "Risks and Uncertainties Facing the Company" section of the company's 2023 Annual Financial Report available on the BIOPHYTIS website (www.biophytis.com) and as set forth in the "Risk Factors" section of Form 20-F and other forms filed with the SEC (Securities and Exchange Commission, USA). We do not undertake any obligation to publicly update or̀ revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.
Contact Biophytis
Investor Relations
Investors@biophytis.com
US Investors
Pascal Nigen - Alpha Bronze
pnigen@alphabronzellc.com
Media contact
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240287
FAQ
What are Biophytis' (ALBPS) main clinical development programs for 2025?
What is the market potential for Biophytis' obesity treatment program?
What strategic partnerships has Biophytis secured recently?
What is the target market size for Biophytis' sarcopenia treatment in China?
What is the main compound being developed by Biophytis for both obesity and sarcopenia?
